Ursapharm Arzneimittel Gmbh

Ursapharm Arzneimittel Gmbh & Co. Kg

Klaus Eschmann

Rainer Maurer

Rolf Müller

Nora Luniak

Josef Beuth

Edyta Grabowska

Klaus Eckert

Disclosed is a composition which comprises a combination ofextract in an amount of at least about 10 &#x3bc;g/mg and seleniumin in an amount from about 0.0001 &#x3bc;g/mg to about 2.0 &#x3bc;g/mg. The composition may further comprise zinc as additional micronutrient. The composition may be formulated as a pharmaceutical or a nutraceutical composition.

[object Object]

The present invention pertains in general to Bromelain and particularly to the different active compounds contained in this complex mixture of proteins. The present invention provides recombinant expressed cysteine proteases, which are found in Bromelain. It has been found that the method for expression of the recombinant proteins is superior to the purification from Bromelain itself.

Recombinant preparation of selected bromelain fractions

The present application pertains to the use of bromelain preparing a medicament for increasing the IL-(8) level in an individual so as to reduce or prevent inflammation in said individual and as an adjuvant therapy during wound healing processes.

Use of bromelain for the treatment of inflammatory diseases and for adjuvant therapy during wound healing processes

The present invention relates to the use of bromelaine proteases for inhibiting blood coagulation, especially for stimulating the production of plasmin, for inhibiting the production of fibrin and for inhibiting the adhesion of human thrombocytes on endothelilum cells. Especially the basic proteases isolable from raw bromelaine have proved to be particularly suitable proteases.

Growing community of inventors

Kleinblittersdorf, Germany

Klaus Eschmann